Ground News

News from medwirenews.com

See all of medwirenews.com news coverage in one place. Discover how medwirenews.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve discovered 4 headlines written by medwirenews.com during the past 3 months.

We’ve assigned a media bias rating of to medwirenews.com. You can read more about our methodology here.

Is medwirenews.com credible or reliable? Our Factuality score answers both of those questions. When it comes to medwirenews.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about medwirenews.com

Where is medwirenews.com located?medwirenews.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top medwirenews.com News

Suresnes · Suresnes

Mixed results for tetramethylpyrazine nitrone treatment in ALS

By Lucy Piper, medwireNews ReportermedwireNews: Tetramethylpyrazine nitrone does not slow overall functional decline in patients with amyotrophic lateral sclerosis, but it may help retain grip strength and is well tolerated, suggest study findings.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier websiteImage credit: © JuanCi Studio / stock.ad…See the Story

Cancer

Vaccine may improve breast cancer treatment outcomes

100% Center coverage: 1 sources

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a recent pilot study. The study combined the HER2-targeting dendritic cell vaccines with standard chemotherapy, demonstrating both safety and positive …See the Story

$Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma$

Cancer

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.See the Story

You've scrolled to the bottom of the feed, there are no more stories.

News from medwirenews.com

News from medwirenews.com

Information about medwirenews.com

Media Bias Ratings

Factuality

Ownership

Top medwirenews.com News

Mixed results for tetramethylpyrazine nitrone treatment in ALS

Vaccine may improve breast cancer treatment outcomes

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

News from medwirenews.com

Information about medwirenews.com

Media Bias Ratings

Factuality

Ownership

Top medwirenews.com News

Mixed results for tetramethylpyrazine nitrone treatment in ALS

Vaccine may improve breast cancer treatment outcomes

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

Cancer-related PE death increase shown in the USA